Curasight is a clinical-stage radiopharmaceutical company focused on developing and commercialising novel and innovative PET imaging ligands for improved diagnoses and risk stratification in cancer.

Curasight's advanced understanding of molecular imaging and cancer biology has resulted in a novel non-invasive imaging-based approach for early identification of high-risk prostate cancer.